APPLICATION OF LATENT HIV-1 INFECTED CELLULAR-MODELS TO THERAPEUTIC INTERVENTION

被引:16
|
作者
BUTERA, ST [1 ]
FOLKS, TM [1 ]
机构
[1] CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333
关键词
D O I
10.1089/aid.1992.8.991
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The 10-year period of clinical latency following infection with the human immunodeficiency virus type-1 remains as a tremendous opportunity for therapeutic intervention. To decipher the viral and cellular mechanisms involved in controlling active and nonproductive viral expression, chromically infected cell lines have been developed which mimic in vivo latency at a cellular level. This review compares these models of chronic infection, emphasizing the advantages and limitations of this approach to the understanding of AIDS progression. In addition, it accentuates the utility of these models of chronic infection in the development and testing of novel drugs aimed at altering the efferent component of the HIV-1 fife cycle. It is this component of the viral life cycle that has remained largely unexplored and open to novel therapeutic strategies for the prevention of lethal immunosuppression.
引用
收藏
页码:991 / 995
页数:5
相关论文
共 50 条
  • [31] Latent HIV-1 gets a shock
    Lichterfeld, Mathias
    NATURE, 2020, 578 (7793) : 42 - +
  • [32] Heterogeneity of HIV-1 latent reservoirs
    Zhao Jia-Cong
    Deng Kai
    中华医学杂志英文版, 2020, 133 (23) : 2867 - 2873
  • [33] Reactivation of Latent HIV-1 in Latently Infected Cells by Coumarin Compounds: Hymecromone and Scoparone
    Li, Xian
    Zeng, Hanxian
    Wang, Pengfei
    Lin, Lu
    Liu, Lin
    Zhen, Pinyi
    Fu, Yuanzhe
    Lu, Panpan
    Zhu, Huanzhang
    CURRENT HIV RESEARCH, 2016, 14 (06) : 484 - 490
  • [34] Excision of Latent HIV-1 from Infected Cells In Vivo: An Important Step Forward
    Feelixge, Harshana S. De Silva
    Jerome, Keith R.
    MOLECULAR THERAPY, 2017, 25 (05) : 1062 - 1064
  • [35] Deficiency in DNA damage response, a new characteristic of cells infected with latent HIV-1
    Piekna-Przybylska, Dorota
    Sharma, Gaurav
    Maggirwar, Sanjay B.
    Bambara, Robert A.
    CELL CYCLE, 2017, 16 (10) : 968 - 978
  • [36] Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection
    Bai, Ruojing
    Lv, Shiyun
    Wu, Hao
    Dai, Lili
    DISEASE MARKERS, 2022, 2022
  • [37] CELLULAR AND MOLECULAR STUDIES OF HIV-1 INFECTED INTRAOCULAR HUMAN NEURAL GRAFTS
    LAZAR, ES
    CVETKOVICH, T
    BLUMBERG, B
    DELCERRO, C
    DZENKO, K
    EPSTEIN, L
    DELCERRO, M
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1993, 34 (04) : 1055 - 1055
  • [38] COMPARISON OF CELLULAR ANTIVIRAL CYTOTOXICITIES PRESENT IN HIV-1 INFECTED HUMANS AND CHIMPANZEES
    WEINHOLD, KJ
    FERRARI, G
    ARTHUR, LO
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (05) : 938 - 938
  • [39] Contributions of HIV-1 Nef to immune dysregulation in HIV-infected patients: a therapeutic target?
    Witkowski, Wojciech
    Verhasselt, Bruno
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (11) : 1345 - 1356
  • [40] A novel therapeutic vaccination delays cART-resistant HIV-1 reservoir rebound in HIV-1 infected humanized mice
    Cheng, Liang
    Li, Guangming
    Li, Dan
    Zhang, Zheng
    Li, Feng
    Zurawski, Sandra
    Zurawski, Gerard
    Levy, Yves
    Su, Lishan
    JOURNAL OF IMMUNOLOGY, 2016, 196